MediSens brings together the clinical and technical community to discuss unmet needs in oncological imaging, with a view to finding solutions from the engineering and medical physics community.
Clinicians will be sharing their view across presentations and panel discussions and with free tickets* available to medical practitioners, we expect there also to be much active dialogue during networking breaks, amongst our exhibitors and the imaging community.
*limited number available
Clinical highlights on the agenda include:
- Professor Nandita deSouza, Professor of Translational Imaging and Co-Director of the MRI Unit, Institute of Cancer Research sharing her insights on our first day’s clinical panel; assessing the unmet needs in oncological imaging, to discuss the current challenges and performance issues with medical imagers and where R&D teams should focus their efforts for improved results.
- Dr John Dickson, Head of Clinical Nuclear Medicine Physics, University College London Hospital, presenting his perspectives on the clinical advantages and quantitative disadvantages of hybrid imaging
- Consideration of what unmet radiological needs could be addressed by PET/MR, including innovative applications for PET/MR in clinical routine from Professor Dr Ambros J. Beer, Radiologist and Nuclear Medicine Physician
- The NHSE diagnostic perspective on AI and machine learning, wider issues and unmet needs, according to Dr Tony Newman-Sanders, Clinical Director, Diagnostic Imaging, Surrey and Sussex Healthcare, National Clinical Director for Diagnostics, NHS England
- Professor Dr Sanjay Gandhi, Professor of Radiology, Research and Innovation Lead, Core Clinical Services, North Bristol NHS Trust, sharing his experiences with advances in computer-aided cancer detection and machine learning; how should radiologists and oncologists embrace this technology?
- Dr Colin Baker, Head of Radiotherapy Physics, Royal Berkshire NHS Foundation Trust and Professor Christopher Nutting, Professor in Clinical Oncology, Royal Marsden Hospital and The Institute of Cancer Research joining a discussion of challenges in imaging for treatment, in terms of image quality and more